NCT03054298 - CAR T Cells in Mesothelin Expressing Cancers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 6, 2017

Primary Completion Date

November 9, 2023

Study Completion Date

July 30, 2024

Conditions

Lung AdenocarcinomaOvarian CancerPeritoneal CarcinomaFallopian Tube CancerMesotheliomas PleuralMesothelioma Peritoneum

Interventions

BIOLOGICAL

huCART-meso cells

Intravenous administration or local delivery of lentiviral transduced huCART-meso cells in 7 cohorts with or without lymphodepletion..

Trial Locations (1)

University of Pennsylvania, Philadelphia

All Listed Sponsors

collaborator

National Institutes of Health (NIH)

NIH

collaborator

Tmunity Therapeutics, a wholly owned subsidiary of Kite Pharma (a Gilead company)

UNKNOWN

lead

University of Pennsylvania

OTHER